Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049515 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
A Phase 3 study, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 3
- Development phase
- 99
- Enrollment target
NCT02049515 is a Phase 3 study that has completed, run by SecuraBio. The registered enrollment target is 99 participants.
The verdict
NCT02049515, a Phase 3 study, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 99 participants
- Enrollment target
Study Summary
A Phase 3 (extension) clinical trial to examine the efficacy of IPI-145 (duvelisib) monotherapy or ofatumumab monotherapy in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with IPI-145 or ofatumumab in study IPI-145-07 (NCT02004522).
Interventions
- DRUG Ofatumumab
- DRUG IPI-145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2013-12 |
| Est. Completion | 2020-06-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02049515
The ClinicalTrials.gov registry entry for NCT02049515 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ofatumumab is the first listed.
NCT02049515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02049515 about?
NCT02049515 is a clinical study titled "A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07". A Phase 3 (extension) clinical trial to examine the efficacy of IPI-145 (duvelisib) monotherapy or ofatumumab monotherapy in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with IPI-145 or ofatumumab in stud...
What is the current status of trial NCT02049515?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2013-12. Estimated completion is 2020-06-12.
What interventions are being tested in trial NCT02049515?
The interventions under investigation include: Ofatumumab (DRUG), IPI-145 (DRUG).
Who is sponsoring clinical trial NCT02049515?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.